# More Effect Without More Side Effects

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/more-effect-without-more-side-effects

> Almost every result in this field trades benefit against harm. Adding cagrilintide to semaglutide produced 6.5 percentage points more weight loss with gut side effects at 53% against 51%.

## Key points

- −18.4% vs −11.9% against semaglutide ALONE, a 6.5 point difference.
- GI disorders 53% vs 51%. Almost nothing in this field adds effect without adding harm.
- But 10% discontinued vs 6%: the cost shows up in dropouts, not in event rates.
- Adding a different mechanism is not the same operation as raising a dose.
- Japan and Taiwan, and 68% men: the opposite of this field's usual skew.

Almost every result on this register trades benefit against harm. A trial comparing cagrilintide–semaglutide against **semaglutide alone** found 6.5 percentage points more weight loss with gastrointestinal side effects at 53% against 51%.[1] That is close to free, which almost nothing in this field is. It is not entirely free, though, and the reason is in the discontinuation column.

## Why the comparator matters

Most trials of a new combination test it against placebo, which answers a question nobody has. Someone already taking semaglutide wants to know whether adding a second agent does anything. This trial randomized 331 adults in Japan and Taiwan to cagrilintide–semaglutide or to semaglutide by itself, for 68 weeks.

*REDEFINE 5 at 68 weeks.[1]*

|   | Cagrilintide–semaglutide | Semaglutide alone |
| --- | --- | --- |
| Weight change | **−18.4%** (SE 0.7) | **−11.9%** (0.7) |
| Difference | **−6.5 percentage points** (95% CI −8.4 to −4.6), p<0.0001 | — |
| Any adverse event | 87% | 84% |
| **Gastrointestinal disorders** | **53%** | **51%** |
| **Discontinued** | **10%** | **6%** |

Cagrilintide is an amylin analog, so it works through a different hormone system from GLP-1 and acts on satiety by another route. That is why adding it is not the same as raising the semaglutide dose, and it is the likely reason the side-effect profile did not simply scale. What it does on its own is covered in [cagrilintide: what the evidence shows](https://glpwatchdog.org/research/cagrilintide-what-the-evidence-shows), and the other amylin drugs in [eloralintide and petrelintide](https://glpwatchdog.org/research/amylin-analogs-petrelintide-eloralintide).

## The pattern this breaks

> **A synthesis of 262 trials concluded that larger benefits in this drug class are generally accompanied by greater harms and more discontinuation**, and this register has found that repeatedly: tripling the semaglutide dose bought 3.1 percentage points and raised abnormal sensation from 6% to 22.9%; survodutide’s higher dose took gut events from 80.9% to 89.7% for 0.8 points. Here, 6.5 points arrived with the gastrointestinal rate essentially unchanged.

The rule still holds for *raising a dose*, where more of the same drug means more of the same effects. Adding a different mechanism is a different operation, and this result suggests it does not carry the same cost.

For where the general pattern comes from, see [what 262 trials say together](https://glpwatchdog.org/research/what-262-trials-say-together); for the clearest examples of it, [what tripling the dose buys](https://glpwatchdog.org/research/what-tripling-the-dose-buys) and [the top dose keeps not being worth it](https://glpwatchdog.org/research/the-top-dose-keeps-not-being-worth-it).

## The column that shows it is not free

> **Ten percent stopped the combination against six percent on semaglutide alone.** That is a real difference, and it is invisible in the side-effect rates. Roughly the same proportion of people had gut symptoms; a larger proportion decided they could not continue.

The difference between how many people *have* an event and how many *quit* runs through this whole literature, and the two point in different directions surprisingly often. An event rate counts occurrences. A discontinuation rate counts the ones that mattered enough to end treatment, which is the only measure that captures severity, duration and how it felt.

In short, the combination buys substantially more weight loss for a modest tolerability cost, and that cost is real and shows up in the place that matters most.

## Who was studied

- **Japan and Taiwan**, which makes this one of the few trials in this field conducted outside Europe and North America.
- **68% men**, the opposite of this field’s usual skew, where trials [over-recruit women](https://glpwatchdog.org/research/who-was-actually-in-the-trials).
- **Around a quarter had type 2 diabetes**, which lowers weight response across this class.
- **Sixty-eight weeks**, with no cardiovascular or other outcome data.

One death occurred, in the semaglutide arm, judged unrelated to treatment by the investigator.

For what “superior” means when this combination is compared in its other trials, see [CagriSema: superior by how much](https://glpwatchdog.org/research/cagrisema-superior-by-how-much).

## Frequently asked questions

### Does adding cagrilintide to semaglutide help?

In this trial, yes: 18.4% weight loss against 11.9% on semaglutide alone over 68 weeks, a difference of 6.5 percentage points. The comparator being semaglutide rather than placebo is what makes that useful.

### Does it cause more side effects?

Gastrointestinal disorders occurred in 53% against 51%, which is essentially unchanged. But 10% discontinued the combination against 6% on semaglutide alone, so the tolerability cost is real and appears in dropouts rather than event rates.

### Why does that differ from raising the dose?

Cagrilintide is an amylin analog acting on a different hormone system. More of the same drug produces more of the same effects; adding a different mechanism appears not to carry the same cost.

### Why does the discontinuation rate matter more than the event rate?

An event rate counts occurrences. A discontinuation rate counts the ones severe or persistent enough to end treatment, which is what determines whether someone gets any benefit.

### Who was in the trial?

331 adults in Japan and Taiwan, followed for 68 weeks. Of them, 68% were men, the opposite of the usual skew in this field, and about a quarter had type 2 diabetes.

## References

1. Yamauchi T, Becker NP, Hagemann CA, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2026. PMID: 42009015. https://pubmed.ncbi.nlm.nih.gov/42009015/

---

Cite as: GLP Watchdog, Nora Bissett, "More Effect Without More Side Effects", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/more-effect-without-more-side-effects

Canonical HTML page: https://glpwatchdog.org/research/more-effect-without-more-side-effects

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
